0001193125-26-202610
SEC filingKyverna Therapeutics appointed Nadia Dac as Chief Commercial Officer effective May 4, 2026, to lead commercial strategy and execution for miv-cel, its late-stage CD19-targeting CAR T-cell therapy in development for stiff person syndrome and other neuroimmunology diseases.
The appointment of Nadia Dac as Chief Commercial Officer represents a pivotal step in Kyverna’s transition from a clinical-stage to a commercial-stage biopharmaceutical company. With over three decades of experience launching therapies in neurology, rare disease, and autoimmune conditions—including Yartemlea® for transplant-associated thrombotic microangiopathy and Vyepti® for migraine prevention—Dac possesses precisely the domain expertise and operational track record required to execute Kyverna’s near-term commercial milestone: the potential launch of miv-cel in stiff person syndrome. This indication has no FDA-approved treatments, positioning miv-cel as a first-in-class, potentially transformative therapy with significant pricing and access leverage. Her background at AbbVie, Biogen, Novartis, and Omeros underscores deep fluency in complex, highly regulated neuroscience markets and in building commercial infrastructure for novel modalities like cell therapy. The inducement grant of 300,000 options—structured under Nasdaq Rule 5635(c)(4) and vesting ratably over four years—reinforces Kyverna’s commitment to retaining mission-critical leadership through the inflection point of regulatory review and launch readiness. Critically, Dac’s mandate extends beyond stiff person syndrome to establishing Kyverna’s broader neuroimmunology franchise, including planned expansion into generalized myasthenia gravis and other B-cell-driven autoimmune diseases. This hire materially de-risks the commercial pathway for miv-cel and signals Kyverna’s confidence in advancing toward revenue generation.